Chemistry:Bimagrumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | ACVR2B |
| Clinical data | |
| Other names | BYM338 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6306H9732N1684O1990S46 |
| Molar mass | 142451.78 g·mol−1 |
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration.[1]
In 2014, Bimagrumab entered Phase II development, with some research indicating clinical effects.[2] Novartis planned to apply in 2016 for FDA approval to treat sIBM patients with bimagrumab.[3]
In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis.[4]
In January 2021, a new study confirmed that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes.[5]
In January 2023 the medication entered phase IIb trials for obesity. [6]
Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half life and is administered once a month. [6]
References
- ↑ "Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)". http://www.novartis.com/newsroom/media-releases/en/2013/1723765.shtml.
- ↑ "Treatment of sporadic inclusion body myositis with bimagrumab". Neurology 83 (24): 2239–46. December 2014. doi:10.1212/WNL.0000000000001070. PMID 25381300.
- ↑ Novartis: Planned filings 2015 to >=2019. Retrieved 27 May 2015.
- ↑ Novartis’ ‘breakthrough’ muscle drug bimagrumab flunks a late-stage trial
- ↑ "Medication shows promise for weight loss in patients with obesity, diabetes" (in en). https://www.eurekalert.org/pub_releases/2021-01/tos-msp011221.php.
- ↑ 6.0 6.1 Healthcare, GlobalData (2023-01-17). "Versanis’ bimagrumab, first-in-class obesity therapy, enters Phase IIb of development" (in en-US). https://www.pharmaceutical-technology.com/comment/bimagrumab-trial-obesity/.
 |
